Symptoms
Fatigue, dizziness and palpitations. Severe and unusual bone and joint pain. Recurrent and severe infections (oral, throat, skin, perianal infections commonly). Fever without obvious infection (but infection should be assumed). Left upper quadrant fullness and early satiety due to splenomegaly (10-20%). Dyspnoea (due to anaemia or large mediastinal mass in those with T-cell tumours). Headache, irritability or altered mental status and neck stiffness (with central nervous system (CNS) involvement). Haemorrhagic or thrombotic complications due to thrombocytopenia or disseminated intravascular coagulopathy (DIC) -for example, menorrhagia, frequent nosebleeds, spontaneous bruising.
Signs
Pallor. Tachycardia and a flow murmur. Nonspecific signs of infection. Petechiae (due to thrombocytopenia), may progress into purpura or ecchymoses. Abdominal distention due to hepatomegaly and splenomegaly. Lymphadenopathy. Testicular enlargement. Gum hypertrophy. Leukaemia cutis [9] . Cranial nerve palsy (especially III, IV, VI and VIII) in mature B-cell ALL.
Primary healthcare professionals need to be aware that haematological cancer can present with a variety of symptoms with a wide differential; they should be prepared to investigate accordingly and urgency of referral should reflect the severity of the symptoms and signs and the findings of investigations [10] . 
Differential diagnosis

Investigations
Blood tests
FBC:
Anaemia is usual and Hb may be below 5 g/L. Thrombocytopenia is also usual, to varying degrees. White blood cell (WBC) count may be high, normal or low but there is usually neutropenia. Leukaemia is unlikely in the presence of a normal FBC but the FBC will not always be abnormal in all cases of ALL, as some patients may not yet have marrow suppression [11] .
If the blood count is abnormal, a blood film is essential to help decide whether leukocytosis is likely to be caused by malignancy or inflammation [1] .
Blood film is likely to show blast cells but can be normal if blast cells are confined to the bone marrow. Clotting: DIC may occur and this produces an elevated prothrombin time, reduced fibrinogen level and the presence of fibrin degradation products. Lactic dehydrogenase levels are usually raised and rapid cell turnover may raise uric acid. Liver and renal function must be checked before initiating chemotherapy.
If fever is present, appropriate steps should be taken to identify and treat infection -eg, blood cultures.
Radiology
CXR may show pneumonia, a mediastinal mass or lytic bone lesions. Testicular ultrasound if the testes are enlarged on examination. ECG, echocardiogram (echo) and/or multiple-gated acquisition (MUGA) scan prior to use of anthracyclines (due to cardiotoxicity).
Haematology, immunology and genetic tests
Bone marrow aspiration and biopsy -World Health Organization (WHO) classification requires 20% or greater amount of blasts in bone marrow and/or peripheral blood for the diagnosis of ALL. Aspiration is the standard procedure with core biopsy only necessary if aspiration does not yield sufficient cells [12] .
Immunophenotyping helps to reveal the subtype. Positive confirmation of lymphoid rather than myeloid origin should be sought by flow cytometric demonstration of lymphoid antigens. Therapeutically, it is important to differentiate between T-cell, mature B-cell and B-cell precursor phenotypes. A negative myeloperoxidase stain helps to diagnose ALL, although acute monocytic leukaemia also gives negative stain with myeloperoxidase.
Testing for bcr-abl (oncoprotein) by polymerase chain reaction (PCR) or cytogenetics may help identify those patients in whom ALL arose as the lymphoblastic phase of chronic myeloid leukaemia (CML).
Classification [13] The French-American-British (FAB) classification has been modified by the WHO as follows: Management [14, 15] Except for those with mature B-cell ALL who receive short-term intensive chemotherapy, treatment for ALL typically consists of remission induction, consolidation (or intensification) and maintenance (or continuation) therapies, CNS prophylaxis as well as management of relapse. Much work has gone into risk assessment and stratification, attempting to limit the most intensive treatment to those at the highest risk of relapse, to spare those at lower risk unnecessary harm from treatment side-effects.
Age-adapted protocols have been developed for adults with ALL. Although there is no uniform consensus, the following age groups are separated [12] :
Adolescents and young adults, defined as from 15/18 years to 35/40 years. Adult ALL, with age range from 35/40 up to 55/60 years, Elderly ALL protocols for patients above the age of >55/60 years. Frail patients not suitable for any intensive therapy, usually considered above the age of 70/75 years.
General supportive treatment
Replacement therapy of blood cells may be required -pre-existing deficiency due to ALL can be profoundly aggravated by chemotherapy. Growth factors may be used to alleviate profound myelosuppression -eg, granulocyte-colony stimulating factor (GCSF) during induction has been associated with faster recovery of neutrophils and platelets and a shorter hospital stay [16] . Antibiotics and antifungal agents may be required to treat opportunistic infection. Allopurinol is often required during induction therapy to control uric acid levels. A central venous catheter is usual, given the frequent requirements for venous access.
Remission induction [12] The goals of induction therapy are:
To eliminate more than 99% of the initial burden of leukaemic cells. To restore rapidly normal haematopoiesis.
To restore previous performance status.
When the diagnosis is established, treatment should start immediately. Pre-phase therapy with corticosteroids (usually prednisone or dexamethasone) alone, or in combination with another drug (eg, vincristine, cyclophosphamide), is often given together with allopurinol and hydration for 5-7 days.
Supportive therapy should be initiated whenever necessary -eg, to treat infections or to substitute platelets or erythrocytes. Severe neutropenia is often seen at diagnosis and is most frequent during induction therapy.
Most induction regimens are centred on vincristine, corticosteroids, and anthracycline (daunorubicin, doxorubicin, rubidazone, idarubicin), with or without cyclophosphamide or cytarabine. L-Asparaginase has been particularly explored in paediatric trials but is now more intensively used in adults. Pegylated asparaginase has the advantage of a significantly longer period of asparagine depletion. Dexamethasone is often preferred to prednisone because it penetrates the blood-brain barrier and also acts on resting leukaemic blast cells.
Current treatment regimes achieve complete remission rates of 80-90%, higher for standard-risk patients at over 90%, and less for highrisk patients at about 75%.
Maintenance [12] Once normal haematopoiesis is achieved, patients undergo maintenance therapy.
Maintenance therapy usually consists of daily 6-mercaptopurine and weekly methotrexate. In some treatment regimens, repeated cycles of vincristine, dexamethasone or other drugs in monthly or longer intervals are given. A treatment duration of 2.5-3 years is usually recommended.
CNS prophylaxis [17] Patients with ALL frequently have meningeal leukaemia at the time of relapse (50-75% at one year in the absence of CNS prophylaxis) and a few have meningeal disease at diagnosis (<10%). Cranial irradiation causes acute and late complications (secondary cancers, neurocognitive deficits, endocrinopathy) so has largely been superseded.
Effective prophylaxis to prevent CNS relapse is an essential part of ALL therapy. Treatment modalities are CNS irradiation, intrathecal methotrexate, intrathecal triple therapy (usually methotrexate, steroids, cytarabine) and systemic high-dose therapy with either methotrexate and/or cytarabine. With a combination of these CNS prophylactic measures, the CNS relapse rate in recent adult ALL trials could be reduced from 10% to less than 5% [12] .
Stem cell transplantation (SCT)
SCT allows intensification of chemotherapies and radiotherapies as it replaces destroyed stem cells. It is difficult to compare it with intensive chemotherapy alone, as there are highly selective criteria to determine suitability for transplant and study numbers are typically small; however, SCT appears to benefit subgroups such as those with a Philadelphia chromosome or poor initial response to treatment. Allogeneic SCT from a sibling or suitable unrelated donors is the main approach for intensive post-induction therapy in patients at high risk of residual disease and relapse [14] .
Treatment of relapse [18] Relapse has a very poor prognosis. Most patients are referred for trial 'salvage' therapies. Factors predicting a good outcome after salvage therapy were:
Young age. Short duration of first remission.
Prevention of recurrence is the best strategy for long-term survival in ALL.
The most commonly used regimens in Europe are fludarabine-and anthracycline-containing regimens -eg FLAG-Ida (fludarabine, highdose ara-C, GCSF and idarubicin) [12] .
New treatment strategies in development include the use of monoclonal antibodies against antigens found on leukaemic cells, cellular immunotherapy and molecular therapeutics [19] .
Editor's Note Danny Buckland, December 2018. A pioneering personalised T-cell (CAR-T) cell therapy for people under the age of 25 with relapsed or refactory B-cell acute lymphoblastic leukaemia (ALL) will be made available through the Cancer Drugs Fund following a recommendation by the National Institute for Health and Care Excellence (NICE) [20] . The therapy -known as Kymriah and given as a single intravenous infusion -involves using a person's own immune cells and modifying them to fight the cancer. It has the potential to be a cure for those who have not responded to current treatment or have relapsed after stem cell transplant.
Complications [21] Most complications that arise are iatrogenic, due to the toxicity of the therapies. Acutely:
Key risks are haemorrhage, anaemia and infection, even with blood replacement therapy. Any fever in a neutropenic patient must be treated as a medical emergency. Hair loss, rashes. Nausea, vomiting, constipation, diarrhoea, mucositis. Electrolyte disturbances. Nephrotoxicity, hepatotoxicity.
Peripheral neuropathy. Psychological disturbances. Tumour lysis syndrome is a risk, especially in children. Uric acid, phosphate and potassium are raised and calcium is low. Treat with alkaline intravenous fluids to aid renal excretion of these products. Electrolyte status should be closely monitored. Stroke from sinus venous thrombosis occurs in about 1 child in 200 but prognosis seems good [22] . Graft-versus-host disease with allograft SCT (can also occur as a chronic condition).
Longer-term complications include:
Cardiomyopathy, arrhythmias. Lung fibrosis. Growth delay [23] . Hypothyroidism. Infertility. Secondary malignancies [24, 25] . Psychosocial effects, impacts on education and occupation [26, 27] .
Increasingly, clinical protocols are being developed to reduce side-effects without sacrificing survival benefits. Drugs with carcinogenic or major organ-damaging effects are being reduced in dose or avoided and pre-conditioning therapies investigated -for example, the use of iron-chelating agents to avoid anthracycline-induced cardiotoxicity. Pharmacogenetics is also being used to predict how patients will respond to treatment [28] .
Prognosis [12] The outcome of ALL is strictly related to the age of a patient, with cure rates from 80-90% in childhood ALL, decreasing to <10% in elderly/frail patients with ALL. Childhood ALL is one of the most curable cancers.
ALL has a poor prognosis in adults because a higher proportion of adults have unfavourable cytogenetic abnormalities, such as the t(9;22) translocation. Many cases present in patients aged over 60 years, who are unlikely to tolerate intensive chemotherapy [1] . Adverse prognostic indicators include age of presentation <12 months or ≥10 years, presenting leukocyte count ≥50 x 10 9 /L, male sex, adverse cytogenetics and extramedullary (eg, CNS) involvement. Early response to chemotherapy seems to be an important positive prognostic indicator both in adults and in children [29] . An extensive review found that although children could obtain remission rates of up to 100%, disease-free survival at ten years was 63% for children and 25-35% for adults [2] . Adolescents have a prognosis between that of children and adults but children under the age of 1 have a cure rate of only about 30%.
Prevention
There are no widely accepted preventative strategies for ALL. Some studies have suggested that breast-feeding confers protection for childhood ALL but this remains controversial [30] .
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